Glycaemic efficacy of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors as add‐on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis

@article{Deacon2012GlycaemicEO,
  title={Glycaemic efficacy of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors as add‐on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis},
  author={Carolyn F. Deacon and Edoardo Mannucci and Bo Ahr{\'e}n},
  journal={Diabetes},
  year={2012},
  volume={14}
}
Aims: During recent years, two strategies of incretin‐based therapy [glucagon‐like peptide‐1 (GLP‐1) receptor agonism and dipeptidyl peptidase‐4 (DPP‐4) inhibition] have entered the market for pharmacological management of type 2 diabetes. A main indication for this therapy is as add‐on to on‐going metformin therapy in subjects with type 2 diabetes who have insufficient glycaemic control with metformin alone. The aim of this study was to compare improvements in glycaemic control and changes in… Expand
Combination therapy of dipeptidyl peptidase‐4 inhibitors and metformin in type 2 diabetes: rationale and evidence
TLDR
The combination of DPP‐4 inhibitors and metformin provides an additive or even synergistic effect on metabolic control in patients with T2DM. Expand
Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes
TLDR
This review focuses on the use ofGLP-1 RAs in the treatment of T2DM, with reference to the differing dominant mechanisms of action between short- and long-acting GLP- 1 RAs and the clinical implications of this difference. Expand
Incretin therapy and its effect on body weight in patients with diabetes.
  • M. Lind
  • Medicine
  • Primary care diabetes
  • 2012
TLDR
Both types of incretin-based therapies for type 2 diabetes have the additional benefits of improving weight management in patients, with GLP-1 receptor agonists causing weight loss and DPP-4 inhibitors being weight neutral. Expand
Lixisenatide as add‐on to oral anti‐diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes
TLDR
Five phase III studies in the GetGoal clinical trial programme assessed the efficacy of lixisenatide, a once‐daily prandial glucagon‐like peptide‐1 receptor agonist, in combination with oral anti‐diabetics in patients with T2DM insufficiently controlled using oral anti-diabetic drugs. Expand
Is there a place for incretin therapies in obesity and prediabetes?
TLDR
Animal studies support the use of incretin-based therapies in prediabetes; however, human data are scarce, and GLP-1 receptor agonist effects are also apparent in non-diabetic obese individuals, so they may have potential for use in the treatment of obesity. Expand
Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short‐acting and other glucagon‐like peptide‐1 receptor agonists
TLDR
The options for treatment intensification will be explored, focusing on drug classes that act via the incretin system and paying particular attention to the short‐acting glucagon‐like peptide‐1 receptor agonists exenatide and lixisenatide. Expand
Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors
TLDR
In conclusion, incretin therapy is safe with very few adverse events and an additional value of the therapy is a very low risk for hypoglycaemia. Expand
Evidence from randomized clinical trials demonstrating improved glycemic control with GLP-1 receptor agonists when used with other agents vs other combination therapy strategies
TLDR
Incretin-based therapies include glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) based therapies, which can be successfully used as part of combination therapy strategies, which is important because type 2 diabetes has multiple pathophysiological defects that need to be addressed to successfully maintain or achieve glucose goals. Expand
Gastrointestinal actions of glucagon‐like peptide‐1‐based therapies: glycaemic control beyond the pancreas
TLDR
Understanding pharmacokinetic and pharmacodynamic differences in GLP‐1 receptor agonists may allow personalized antihyperglycaemic therapy in type 2 diabetes, and provide the rationale to explore treatment in patients with no or little residual β‐cell function. Expand
Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice.
  • G. Umpierrez, L. Meneghini
  • Medicine
  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2013
TLDR
Incretin-based therapies are characterized by an overall favorable safety profile and weight effect, a low risk of hypoglycemia, and clinically meaningful improvements in HbA1c. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 45 REFERENCES
Dipeptidyl Peptidase‐4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP‐1
TLDR
The study results show that metformin is not a DPP‐4 inhibitor but rather enhances precursor GCG expression in the large intestine, resulting in increased total GLP‐1 concentrations, which have complementary mechanisms of action and additive effects with respect to increasing the concentrations of active GLP-1 in plasma. Expand
Incretin‐based therapies – review of the physiology, pharmacology and emerging clinical experience
TLDR
In this review, aspects of incretin biology and pharmacotherapy are addressed with a view to highlighting potentially clinically relevant issues and areas of basic research that may impinge on these. Expand
Incretin based therapies for type 2 diabetes mellitus.
TLDR
Therapeutic approaches for enhancing the incretin action include degradation resistant GLP-1 receptor agonists (incretin mimetics) and inhibitors of dipeptidyl peptidase-IV (DLP-IV) activity (Incretin enhancers- gliptins). Expand
Efficacy and safety of adding the dipeptidyl peptidase‐4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double‐blind, placebo‐controlled study
Aims:  To evaluate the efficacy and safety of alogliptin, a new dipeptidyl peptidase‐4 inhibitor, for 26 weeks at once‐daily doses of 12.5 and 25 mg in combination with metformin in patients whoseExpand
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
TLDR
This 18‐week, phase 3b, multicentre, double‐blind, noninferiority trial compared the efficacy and safety of two dipeptidyl peptidase‐4 inhibitors, saxagli leptin and sitagliptin, in patients whose glycaemia was inadequately controlled with metformin. Expand
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
TLDR
Liraglutide was superior to sitagliptin for reduction of HbA(1c), and was well tolerated with minimum risk of hypoglycaemia, supporting the use of liragLutide as an effective GLP-1 agent to add to metformin. Expand
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin
  • B. Ahrén
  • Medicine
  • Vascular health and risk management
  • 2008
TLDR
Both fasting and prandial glucose are reduced by DPP-4 inhibition in combination with metformin in association with improvement of insulin secretion and insulin resistance and increase in concentrations of active GLP-1. Expand
Efficacy and Safety of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Compared with Exenatide Twice Daily and Sitagliptin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
TLDR
Compared with other incretin-based therapies, LA-GLP-1RAs produce greater improvement in A1C and FPG and result in a potentially favorable adverse event profile compared with exenatide twice daily. Expand
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
TLDR
In patients with type 2 diabetes, near maximal glucose-lowering efficacy of sitagliptin after single oral doses was associated with inhibition of plasma DPP-4 activity of 80% or greater, corresponding to a plasma sitgliptin concentration of 100 nm or greater and an augmentation of active GLP-1 and GIP levels of 2-fold or higher after an OGTT. Expand
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
  • B. Ahrén
  • Medicine
  • Diabetes, metabolic syndrome and obesity : targets and therapy
  • 2010
TLDR
Sitagliptin has in several clinical studies been shown to improve metabolic control in type 2 diabetes, both when used as monotherapy and when used in combination with metformin, sulfonylurea, thiazolidinediones or insulin. Expand
...
1
2
3
4
5
...